SAN FRANCISCO, Jan. 27, 2014 (GLOBE NEWSWIRE) -- CollabRx, Inc. (Nasdaq: CLRX ), a data analytics company focused on informing clinical decision making in molecular medicine, and CellNetix Pathology & Laboratories, LLC, a leading anatomic pathology testing and services provider, today announced a multi-year agreement to access CollabRx technology and content resources in support of the clinical interpretation of genetic sequencing-based tests provided by CellNetix.
Under the terms of the agreement, CollabRx medical and scientific knowledge will be incorporated into the results of genetic sequencing-based tests in oncology provided by CellNetix. CellNetix will leverage CollabRx's dynamically updated knowledgebase in molecular medicine, ensuring that the latest medical and scientific data is made available to ordering physicians to aid in their interpretation of test results and inform patient treatment planning. CollabRx's knowledgebase includes the clinical impact of specific genetic profiles and is supported by its large and growing network of over 75 leading clinical practitioners in the U.S. and Europe.
The partnership will leverage each company's commitment to developing cutting edge technology infrastructure and information system applications to integrate, automate, and standardize molecular testing and reporting in oncology. These capabilities are of particular significance in the large-scale molecular analysis of tumors using clinical genetic sequencing, given the sheer volume and complexity of genetic data that is produced. While genetic sequencing based tests are increasingly becoming an important part of the clinical management of cancer patients, the resulting explosion of data is thus far outpacing the ability of practicing physicians to understand how to apply this genetic data in treating their patients.
"CollabRx has developed a highly scalable technology platform and process to provide a key part of the diagnostic test report for clinical genetic sequencing in cancer," said Pat Cooke, CIO & Executive Director of Business Operations at CellNetix. "These IT tools and services are essential to dynamically associate the latest medical and scientific knowledge with the results of tumor mutation profiling conducted by CellNetix. We are excited to work with CollabRx to provide a best in class medical informatics solution that will enable physicians to take a tumor's molecular characteristics into consideration when determining a cancer treatment plan."
"CellNetix has combined peer-to-peer collaboration and clinical expertise with technological innovation to dramatically impact the delivery of healthcare by individual physicians and hospital systems," said Thomas Mika, Chairman, President & CEO of CollabRx. "CollabRx is privileged to partner with CellNetix, the largest and most comprehensive pathology company in the Pacific Northwest, to link clinical genetic sequencing test results with expert-vetted therapy considerations to result in the best possible care for cancer patients."
The partnership with CellNetix represents the CollabRx's first such relationship with a large and influential private pathology company and demonstrates the Company's accelerating pace of business and channel development in 2014. This new milestone attests to the growing adoption of CollabRx technology and interpretive analytics in top-tier laboratories worldwide as a standard aspect of test reporting for clinical genetic sequencing in cancer and other diseases.
About CollabRx
CollabRx, Inc. (Nasdaq: CLRX ) is a recognized leader in cloud-based expert systems to inform healthcare decision-making. CollabRx uses information technology to aggregate and contextualize the world's knowledge on genomics-based medicine with specific insights from the nation's top cancer experts, starting with the area of greatest need: advanced cancers in patients who have effectively exhausted the standard of care. More information may be obtained at http://www.collabrx.com .
About CellNetix
CellNetix Pathology & Laboratories, LLC is a dynamic, rapidly growing private pathology company headquartered in Seattle, Washington, and serving hospitals and clinics throughout Washington, Oregon, Idaho and Alaska. CellNetix employs over 50 pathologists and provides comprehensive subspecialized anatomic pathology services at its central state-of-the-art anatomic pathology laboratory in Seattle. Recently PAML – a Spokane, WA based national clinical reference lab - joined forces with CellNetix to offer AP reference lab services to a national market. More information may be obtained at http://www.cellnetix.com and at http://www.paml.com .
CollabRx Safe Harbor Statement
This press release includes forward-looking statements about CollabRx's anticipated results that involve risks and uncertainties. Some of the information contained in this press release, including, but not limited to, statements as to industry trends and CollabRx's plans, objectives, expectations and strategy for its business, contains forward-looking statements that are subject to risks and uncertainties that could cause actual results or events to differ materially from those expressed or implied by such forward-looking statements. Any statements that are not statements of historical fact are forward-looking statements. When used, the words "believe," "plan," "intend," "anticipate," "target," "estimate," "expect" and the like, and/or future tense or conditional constructions ("will," "may," "could," "should," etc.), or similar expressions, identify certain of these forward-looking statements. Important factors which could cause actual results to differ materially from those in the forward-looking statements are detailed in filings made by CollabRx with the Securities and Exchange Commission. CollabRx undertakes no obligation to update or revise any such forward-looking statements to reflect subsequent events or circumstances.
CollabRx Contacts: Gavin J. Gordon, MBA, PhD Vice President of Business Development & Strategic Alliances CollabRx, Inc. 415-248-5350 or James Carbonara Hayden IR 646-755-7412 CellNetix Contact Don Howard, MD, PhD Chairman and Chief Executive Officer CellNetix Pathology & Laboratories 206-576-6502
